Indena’s bilberry extract may help to fight dry eye conditions, says study

83d31555-648e-4bee-90c0-d443589c51ebarticleimage.jpg

08 Sep 2017 --- Indena has reported that its Mirtoselect bilberry extract may have an important role in “preserving adequate aqueous levels” in people possibly experiencing dry eye conditions. This is according to a new randomized, double-blind, placebo-controlled clinical study published in the European Review for Medical and Pharmacological Sciences.

“Mirtoselect through the beneficial effect on vascular circulation can improve oxygen and blood delivery to the eye restoring the functionality of tear secretion,” Antonella Riva, Product Research Manager at Indena, tells NutritionInsight. “Furthermore, the free radical scavenging properties counteract one of the major risk factors of DED, the oxidative stress.”

“It shows consistent health clinical benefits especially for eye health,” Riva adds. “This consistency is due to a deep attention to biomass collection, storage and reproducible batch-to-batch industrial production and its unique composition. Clinical findings are also linked with an optimal tolerability profile.”

Study shows tear production benefits
The aim of the study was to investigate the ability of bilberry extract to maintain adequate tear levels and to confirm its antioxidant potential, Indena notes in its press release. A total of 21 healthy subjects experiencing dry eye were enrolled and randomly assigned to receive supplementation with Mirtoselect, the Indena proprietary standardized bilberry extract that is said to contain 36 percent anthocyanins. The supplementation was with two tablets corresponding to 160mg daily or placebo for four weeks.

The results of Schimer’s test – indicating the volume of tear secretion – before and after the four-week period showed significant improvements in the mean values for the right eye and both eyes as well as a beneficial tendency for the left eye in the supplemented group, Indena reports. In the placebo group, the mean values of Schimer’s test at the end of the treatment were not significant.

“Aged people or those exposed to certain stress conditions for the eye (i.e. dust or dry environment) may experience discomfort, visual disturbance, and tear film instability with potential impairment of the ocular surface,” comments Riva. “Mirtoselect is supported by a strong clinical literature, confirming its efficacy profile in the realm of vascular health and ophthalmology. This last study opens a new application for our bilberry extract in subjects with visual fatigue and a higher tendency of dry eye. The observed antioxidant potential is of a great importance due to the fact that a potential relationship between dry eye and relative oxygen species is reported.”

“The history of Indena Mirtoselect dates back to 1970 [and] our standardized bilberry extract is supported by more than 30 published clinical trials,” says Cosimo Palumbo, Indena Marketing Director. “This is one of the best examples of how Indena pioneers the development of botanical-derived dietary ingredients, confirming its expertise in innovation and quality. We are extremely proud that today Mirtoselect is the only bilberry extract (Vaccinium myrtillus) supported by clinical data on this specific eye condition.”

The study by Riva A. et al., “The effect of a natural, standardized bilberry extract (Mirtoselect) in dry eye: a randomized, double blinded, placebo controlled trial,” can be found in the European Review for Medical and Pharmacological Sciences

“The major applications investigated so far for Mirtoselect are in the realms of vascular health and ophthalmology (eye protection at the retina level), but epidemiological surveys, animal models and pilot clinical studies suggest a broader clinical profile of anthocyanins encompassing memory improvement, gastrointestinal and cardiovascular health,” Palumbo tells NutritionInsight of possible future commercial applications of Mirtoselect. “In particular, preliminary trials have shown potential metabolic syndrome and glucose metabolism management activity with the use of Mirtoselect (Hoggard N.), which may represent an opportunity as future application further to the continuing research in the eye health field of use.”

Asked about any further studies to investigate Mirtoselect’s benefits, Riva adds: “We have just completed a new clinical trial in retinopathies showing a good improvement of the electrophysiological response of the nervous system to visual stimuli in the responsive subjects.”

By Paul Creasy

To contact our editorial team please email us at editorial@cnsmedia.com

Indena S.p.A.

Collapse

Indena is the world's leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.

Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research)  and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

The key to Indena's success is its research, covering: the screening of medicinal plants for pharmacological benefits; the identification of new active principles; the development of cutting-edge extraction and purification systems for industrial applications.

Phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestige universities and private research institutes in the biological assessment of the safety and effectiveness of its products up to clinical phase I/II.

A key strategic research objective is the development of new active principles for pharmaceutical applications. This also forms an indispensable base for the health-food and personal care industries.

The pharmaceutical side of the company is focused mainly on anti-cancer drugs, which are produced to US-FDA, ICH and EU standards at Indena's High Containment Manufacturing facilities in Settala, Italy. Indena's drug discovery strategy is to develop new chemical entities up to "Phase I/II" of clinical studies, and then license them to pharmaceutical companies.

Today Indena is also concentrating its efforts on the industrial production of high-quality standardised botanical derivatives, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and prevent damage caused by free radicals.

Backed by more than 90 years of botanical experience, Indena has developed a plantation network, managed by experts, to supply its research and production centres with officinal plants, while ensuring bio-diversity and protecting the ecosystem from uncontrolled harvesting. Today more than 60% of the raw material used in manufacturing comes from cultivations.

Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations. There is constant communication and interaction between the company's experts, who cooperate on the updating of all the main pharmacopoeias, and the major international regulatory authorities such as WHO, EMA, and ESCOP.
The company has more than 150 primary patents and has published more than 700 scientific studies.

Related Articles

Nutrition & Health News

Targeting aching joints: A key theme at Vitafoods Europe 2018

21 May 2018 --- World populations are getting older and with age, the risk of bone and joint health issues – such as rheumatoid arthritis and osteoarthritis – increases. Moreover, joint health concerns also affect younger consumers, such as so-called “weekend warriors,” who exercise once or twice a week, meaning that the joint health market is of interest not just to senior citizens but also to any consumers seeking to live an active life. Among the different innovative healthy aging and lifestyle solutions presented at Vitafoods Europe this year, there was a clear spot for ingredients aimed at supporting joint health.

Nutrition & Health News

Weekly Digest: Valensa's Saw Palmetto gains sustainable logo

18 May 2018 --- The past week saw Valensa International gain sustainable recognition with the Fresh from Florida logo for their Saw Palmetto product, as well as USP’s (United States Pharmacopeia) Dietary Supplement Verification Program nabbing the top spot for reliability as determined by pharmacists in a survey conducted by the Pharmacy Times. Furthermore, in clinical news, omega 3 and omega 6 were found to aid the regulation of blood glucose levels in rats. The findings open up the potential for the use of supplements in type 2 diabetes regulation.

Nutrition & Health News

Nutricosmetics: Seppic launches ingredient dedicated to sensitive skin 

18 May 2018 --- French specialty ingredients company Seppic has launched Sepibliss, a nutricosmetic active ingredient dedicated to reactive and sensitive skins. Sensitive skin is a global and growing problem due to multiple aggressions such as pollution, weather conditions, emotional stress or food habits. Sepibliss aims to handle this concern in a new innovative way, by soothing these reactions by oral route.

Nutrition & Health News

BGG & Solix Algredients combine to expand functional ingredient NPD and portfolio

18 May 2018 --- BGG and Solix Algredients, Inc. have joined forces to form a new company supplying functional ingredients originating from three sectors: algae, fruits and plants. The new company hopes for particular strength in innovative product combinations and the natural astaxanthin market. The portfolio will include natural astaxanthin, DHA Omega-3 fatty acids, Vitamin E tocotrienols, apple polyphenols and fruit/berry extracts for the food/beverage, personal care and feed markets. 

Nutrition & Health News

US safety watchdog to US FDA: “Add warning labels to ginkgo biloba supplements”

16 May 2018 --- The Center for Science in the Public Interest (CSPI) is urging consumers to avoid supplements made with ginkgo biloba, which they claim can be adulterated. They propose that the supplement is ineffective in improving memory and circulation. The agency has compiled a letter to the FDA’s Office of Dietary Supplement Programs requesting warning labels on ginkgo packages.

More Articles
URL : http://www.nutritioninsight.com:80/news/indenas-bilberry-extract-may-help-to-fight-dry-eye-conditions-says-study.html